-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Imunon (NASDAQ:IMNN) Shares Down 2.8%
Imunon (NASDAQ:IMNN) Shares Down 2.8%
Shares of Imunon, Inc. (NASDAQ:IMNN – Get Rating) traded down 2.8% on Thursday . The company traded as low as $1.38 and last traded at $1.38. 20,449 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 124,634 shares. The stock had previously closed at $1.42.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Brookline Capital Management reiterated a "buy" rating on shares of Imunon in a research report on Monday, November 14th. Alliance Global Partners assumed coverage on Imunon in a research report on Thursday, October 13th. They issued a "buy" rating and a $15.00 price objective on the stock.
Get Imunon alerts:Imunon Stock Down 2.8 %
The company has a debt-to-equity ratio of 0.13, a current ratio of 4.75 and a quick ratio of 4.75. The business has a fifty day simple moving average of $1.51.
Imunon (NASDAQ:IMNN – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.06). Imunon had a negative return on equity of 56.47% and a negative net margin of 5,377.20%. The business had revenue of $0.13 million during the quarter, compared to analysts' expectations of $0.11 million. On average, sell-side analysts anticipate that Imunon, Inc. will post -4.14 EPS for the current fiscal year.Imunon Company Profile
(Get Rating)
Imunon, Inc, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
Read More
- Get a free copy of the StockNews.com research report on Imunon (IMNN)
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Imunon, Inc. (NASDAQ:IMNN – Get Rating) traded down 2.8% on Thursday . The company traded as low as $1.38 and last traded at $1.38. 20,449 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 124,634 shares. The stock had previously closed at $1.42.
伊蒙股份有限公司(納斯達克代碼：IMNN-GET Rating)股價週四下跌2.8%。該公司股價低至1.38美元，最新報1.38美元。午盤成交量為20,449股，較124,634股的平均成交量下降84%。該股此前收盤價為1.42美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of equities research analysts have recently weighed in on the company. Brookline Capital Management reiterated a "buy" rating on shares of Imunon in a research report on Monday, November 14th. Alliance Global Partners assumed coverage on Imunon in a research report on Thursday, October 13th. They issued a "buy" rating and a $15.00 price objective on the stock.
一些股票研究分析師最近對該公司進行了分析。Brookline資本管理公司在11月14日星期一的一份研究報告中重申了對Imunon股票的“買入”評級。Alliance Global Partners在10月13日星期四的一份研究報告中對Imunon進行了報道。他們對該股給予了“買入”評級和15.00美元的目標價。
Imunon Stock Down 2.8 %
Imunon股價下跌2.8%
The company has a debt-to-equity ratio of 0.13, a current ratio of 4.75 and a quick ratio of 4.75. The business has a fifty day simple moving average of $1.51.
該公司的債務權益比為0.13，流動比率為4.75，速動比率為4.75。該業務的50天簡單移動均線為1.51美元。
Imunon Company Profile
Imunon公司簡介
(Get Rating)
(獲取評級)
Imunon, Inc, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
Imunon公司是一家臨床階段生物技術公司，專注於基於DNA的免疫療法、疫苗和定向化療的開發和商業化。它的產品線包括GEN-1，一種用於卵巢癌局部治療的基於DNA的免疫療法；以及ThermoDox，一種阿黴素的專有熱激活脂質體膠囊，正處於各種癌症適應症的開發階段。
Read More
閱讀更多內容
- Get a free copy of the StockNews.com research report on Imunon (IMNN)
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- 在Imunon上免費獲取StockNews.com的研究報告(IMNN)
- 這就是為什麼達科電子在一天內下跌了40%
- 是時候在Gamestop上認輸了嗎？
- 為什麼你應該避免Carvana，即使它可以避免破產
- 投資者是否聽到了Spotify下跌趨勢的終結？
- 美聯儲軸心的問題不是是否，而是何時，這是為什麼
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Imunon日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Imunon和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧